Zydus Cadila gets USFDA nod for anti-fungal ointment

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram and 1 mg/gram, the company said in a BSE filing.

PTI

November 12, 2018 / 12:07 IST

Aurobindo Pharma Ltd.

Zydus Cadila on Monday said it has received final approval from the US health regulator to market Nystatin and Triamcinolone Acetonide Ointment, used in the treatment of fungal skin infections.

Zydus Cadila has received the final approval from the United States Food and Drug Administration (USFDA) to market Nystatin and Triamcinolone Acetonide Ointment USP, 100,000 units/gram and 1 mg/gram, the company said in a BSE filing.

Zydus Cadila said the drug will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group has more than 226 approvals, and so far filed over 330 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

PTI

first published: Nov 12, 2018 11:55 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347